ClinicalTrials.gg
Not yet recruitingNCT05530083Updated Oct 3, 2022

Group Education Helps Smoking Cessation and Hypertension Control

An interventional study of group education and conventional smoking cessation management in Smoking Cessation and Hypertension, sponsored by Shanghai Jiao Tong University School of Medicine. Not yet recruiting. Open to male participants aged 65 Years to 84 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-03.

Sponsored by Shanghai Jiao Tong University School of Medicine · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
65 Years to 84 Years
Sex
Male
01

Study summary

Smoking elderly males with stage 1 and 2 hypertension who currently smoked at least one cigarette per day and were willing to quit smoke will be invited to this cluster randomized, controlled, interventional, open clinical trial. The investigators will provide participants with group education of smoking cessation and their blood pressure measured at clinic at the sixth month is the primary endpoint. The investigators aim to explore how group education of smoking cessation effects smoking cessation, hypertension control and cardiovascular events.

02

Conditions studied

  • Smoking Cessation
  • Hypertension

Keywords

  • group education
  • smoking cessation
  • blood pressure
03

In context

Smoking Cessation

1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 163 across 1,425 interventional studies indexed under Smoking Cessation.

Browse Smoking Cessation studies →

Lead sponsor

Shanghai Jiao Tong University School of Medicine is the lead sponsor of 374 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 84 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed the
  • aged 65 to 84
  • new-onset hypertension or poorly controlled hypertension (140mmHg≤systolic blood pressure\<180mmHg and (or) 90mmHg≤ diastolic blood pressure\<110mmHg)
  • smoked last week and smoked more than 1 cigarette per day on average
  • be willing to quit smoking
  • can communicate normally and cooperate in blood pressure measurements, finishing questionnaires
  • complete interventions and follow-up consistently

Exclusion criteria

Exclusion Criteria:

  • home systolic blood pressure\<130mmHg and (or) home diastolic blood pressure\<80 mmHg
  • severe communication difficulties (aphasia, hearing impairment, etc.)
  • suffering from mental disorders such as anxiety and depression
  • cancer confirmed
  • with previous serious cardiovascular events such as acute coronary syndrome, acute left heart failure, stroke or with specific cardiovascular therapeutic device such as pacemakers
  • other serious physical illness or illness identified by investigators that unable to participant in study
  • using specific non-permitted medication currently
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Experimental
    group education

    The investigators will provide experimental groups with group education of smoking cessation, including lectures in groups of 50 to 100 people and panel discussion in groups of 5 to 10 people.

    Behavioral: group education

  • Other
    conventional smoking cessation management

    The investigators will provide control groups with conventional smoking cessation management, including regular follow-up of smoking status and giving advice of smoking cessation.

    Behavioral: conventional smoking cessation management

Interventions

  • Behavioralgroup education

    Group education is one of strategies and behavioural interventions of smoking cessation. Lectures, group meeting for mutual support, discussion of coping skills and suggestions for prevention relapse can help smokers quit smoking by providing support and encouragement from people in same condition.

  • Behavioralconventional smoking cessation management

    Including regular follow-up of smoking status and giving advice of smoking cessation

06

What researchers measure

Primary outcomes

  1. change of clinic systolic blood pressure from baseline at the sixth month

    Time frame: 6 months

Secondary outcomes

  1. Cardiovascular events (cardiovascular death, stroke,myocardial infarction)

    Time frame: 6 months, 1 year, 2years, 3 years

  2. change of clinical blood pressure and home blood pressure from baseline

    Time frame: 1 month, 2 month, 3 month, 6 month, 1 year, 2 years, 3 years

  3. Hypertension control rate

    Time frame: 1 month, 2 month, 3 month, 6 month, 1 year, 2 years, 3 years

  4. Biochemical smoking cessation rate

    CO≤6 ppm

    Time frame: 6 months

  5. Self-reported 7-days smoking cessation rate

    Time frame: 1 month, 2 month, 3 month, 6 month, 1 year, 2 years, 3 years

  6. Self-reported long-term smoking cessation rate

    Participants hadn't smoked for at least one month.

    Time frame: 1 month, 2 month, 3 month, 6 month, 1 year, 2 years, 3 years

  7. Self-reported average number of cigarettes smoked per day

    Time frame: 1 month, 2 month, 3 month, 6 month, 1 year, 2 years, 3 years

  8. Relapse rate

    Time frame: 6 month

  9. Mini-Mental State Examination score

    The cognitive function of participants will be assessed by MMSE. The score of MMSE ranges from 0 (worse) to 30 (better).

    Time frame: 6 months

  10. FEV1-Pulmonary functions

    Forced expiratory volume in 1 second (FEV1) is the volume of air exhaled in the first second during forced exhalation after maximum inspiration.

    Time frame: 6 months

  11. PEF-Pulmonary functions

    Peak expiratory flow (PEF), the maximal flow that can be exhaled when blowing out at a steady rate.

    Time frame: 6 months

  12. FVC-Pulmonary functions

    Forced vital capacity (FVC), is the maximum amount of air that can be exhaled when blowing out as fast as possible.

    Time frame: 6 months

  13. Fagerstrom Test for Nicotine Dependence score

    The score of FTND ranges from 0 to 10. Participants with higher scores have higher degree of tobacco dependence and are less likely to maintain the status of smoking cessation.

    Time frame: 6 months

  14. Carbon monoxide concentration breathed

    Time frame: 6 months

  15. Adverse events, including nicotine withdrawal symptoms and other adverse events.

    Nicotine withdrawal symptoms were quantified using the Minnesota Tobacco Withdrawal Scale (MNWS).

    Time frame: 1 month, 2 month, 3 month, 6 month, 1 year, 2 years, 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2022; primary completion for Jan 2027, 50 months later.

Of 547 non-industry interventional studies with no phase under Smoking Cessation, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 50 months is above that.

Counting every sponsor, half of 564 studies reached it within 24 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2022
First posted
Sep 7, 2022
StartEst.
Oct 12, 2022
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Oct 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05530083
Responsible party
Ji-Guang Wang (Director of the Shanghai Institute of Hypertension and the Department of Hypertension, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
Sep 7, 2022
Start date
Oct 12, 2022 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Oct 3, 2022

Study contacts

Jiguang Wang, PhD
Contact
jiguangw@163.com
+86-21-64370045 ext. 610911

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion